| HS Code | 835683 |
| Iupac Name | tert-butyl (3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate |
| Molecular Formula | C39H45FN2O5 |
| Molecular Weight | 640.79 g/mol |
| Appearance | White to off-white solid |
| Solubility | Sparingly soluble in water, soluble in organic solvents |
| Chirality | (3R,5R) |
| Functional Groups | tert-butyl ester, dihydroxy, amide, fluoroarene, isopropyl, pyrrole |
| Pharmacological Class | Potential statin/analogue |
| Logp | Estimated 6.2 |
| Storage Conditions | Store in a cool, dry place, protected from light |
As an accredited tert-butyl (3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | White, opaque, screw-cap bottle containing 5 grams of tert-butyl (3R,5R)…heptanoate; labeled with chemical name, hazard symbols, and batch number. |
| Container Loading (20′ FCL) | Container loading (20′ FCL): Securely packed 20-foot container, chemical in sealed drums or IBCs, labeled per transport regulations, ensuring safe delivery. |
| Shipping | This chemical is shipped in tightly sealed, chemically resistant containers, protected from light and moisture. Transport follows all relevant regulations for hazardous substances, including labeling and documentation. Temperature is controlled as required to ensure stability. Handling by authorized personnel only, with appropriate safety measures to prevent exposure or environmental release during transit. |
| Storage | Store tert-butyl (3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate in a tightly closed container, protected from light and moisture, at 2–8 °C (refrigerator). Store in a well-ventilated, dry area away from incompatible substances such as strong acids and oxidizers. Label clearly and follow standard laboratory safety protocols for handling and storage of chemicals. |
| Shelf Life | Shelf life: **Stable for 2 years when stored in a cool, dry place, protected from light, moisture, and excessive heat.** |
As an established manufacturer specializing in advanced statin intermediates, we supply tert-butyl (3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate for select, highly regulated downstream applications. We partner directly with pharmaceutical and chemical production plants, supporting their compliance and quality assurance systems with consistent quality and traceability for high-throughput environments.
This intermediate serves as a strategic building block in the process route for the industrial synthesis of high-potency statin APIs, especially for rosuvastatin and related analogues. Its stereochemically defined structure matches closely to downstream chiral intermediates. Bulk synthesis plants add the tert-butyl ester at late-stage coupling, relying on stringent enantiopurity and impurity control. This material meets current GMP expectations at the intermediate stage, streamlining post-condensation transformations prior to deprotection and salt formation steps in API production. QC labs monitor optical purity and residual solvents in every batch before it progresses toward the final API reactors and purification.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Innovator and generics-focused CROs source this material for process development, scale-up validation, and impurity fate studies for statin molecules. The defined tert-butyl ester configuration enables systematic optimization of synthetic steps, including kinetic resolution, purification, and characterization in non-clinical and pilot scale facilities. It is employed primarily in closed-system reactors for stepwise transformation, supporting regulatory submission packages and process patent drafting. Analytical teams use this intermediate to refine HPLC and chiral detection methods aligned with regulatory expectations for impurity profiling and batch release testing of downstream APIs.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Regulatory-approved generic manufacturers utilize this intermediate within their closed-loop production chains for registered statin drugs. Following the completion of the full API synthetic route, this material’s traceability ensures seamless transfer between API production and finished dosage formulation lines, such as direct tablet or capsule production with integrated in-process controls. Our strict impurity specification aligns with regulatory expectations for both intermediate and final dosage forms, supporting large-scale, continuous output with minimized deviation risk during process validation and commercial production campaigns for global markets.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Biotech and pharmaceutical discovery teams order this material for custom library synthesis and lead candidate optimization, targeting novel pyrrole-based cholesterol-lowering agents. Synthetic chemists use it for targeted scaffold modifications and side chain diversification studies. The raw material’s stability and steric protection facilitate late-stage introduction of sensitive or functionalized moieties during medicinal chemistry campaigns, accelerating route scouting and enabling production of differentiated analogs under tightly controlled small-scale or kilo-lab conditions.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Competitive tert-butyl (3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8618005193850 or mail to sales8@bouling-chem.com.
We will respond to you as soon as possible.
Tel: +8618005193850
Email: sales8@bouling-chem.com
Flexible payment, competitive price, premium service - Inquire now!
In the landscape of complex pharmaceutical development, the pursuit of molecules that deliver nuanced biological activity and structural consistency has defined the last decade of innovation. Over this same period, our team has leaned into small-molecule synthesis, taking on ever more challenging targets. tert-Butyl (3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate stands out among these, not only for its intricate design but for the sheer investment of scientific and technical effort behind its reliable production.
This compound’s structure reflects the shift towards highly specific synthons required by today’s medicinal chemists. Each component—from its sterically protected dihydroxyheptanoate backbone to the tailored pyrrole ring bristling with fluorinated and phenyl substituents—serves a purposeful function in downstream synthetic schemes.
In our facility, we take the chiral purity of the (3R,5R) diastereomer with utmost seriousness. Solid-phase and solution-phase synthesis approaches both play roles, but the optimization has always leaned on practical problems: how to maintain control at every stereocenter, how to protect the tert-butyl group without introducing hard-to-remove side products, and how to avoid off-pathway isomers that complicate purification and analysis. HPLC and NMR checks, validated by mass spectrometry, give us benchmarks batch over batch, which translates directly into the confidence our customers expect.
Over many years, this molecule found its calling in the pathways behind cholesterol absorption inhibitors and related metabolic research. The specific arrangement of the pyrrole core—antenna-like aryl groups, isopropyl branching, and fluorinated aromatic moiety—serves as a privileged scaffold for interactants in cardiovascular and metabolic target screening.
We often field questions from process chemists and project leaders about how such a substituted framework holds up to multiple transformations in a medicinal chemistry workflow. Through repeated hydrogenations, amide couplings, and ester-cleavage sequences, we have designed routes where protecting group strategies do not impede the installer’s productivity. For decades, our feedback loops with collaborating pharmaceutical groups helped clarify what matters: exacting purity, minimization of non-volatile side impurities, and supply chain resilience. We keep our analytics tuned for both process-related impurities from early synthetic steps and degradation products that can accumulate during storage.
Specification should serve research, not become a hurdle. We commit extensive time characterizing melting point, optical rotation, water content, and impurity profile for each lot. But the underlying philosophy is simpler: if a bench chemist runs into a separation issue in the downstream process, or detects lingering trace mineral acids from a previous step, project progress stalls. This motivated an integrated approach that brings QA and R&D staff together. Our specifications grow out of experience—what works, what doesn’t, how even a trace contaminant can throw off crystallization in structurally similar analogs.
Documentation is written with the scientist in mind. Instead of leaning on vague minimum purity claims, we present full chromatograms with annotated peak assignments, optical purity data, and batch analyses that tell the story of each synthesis. Researchers find this especially meaningful when moving from small-scale tests to kilo-scale runs: scale-up often reveals what paper procedures gloss over, such as trace oxidant residues or byproducts that only show up when batch weights multiply. We've learned from scaling, and we feed those findings right back into our release criteria.
Model numbers or catalog codes offer a convenient handle for ordering, but in the lab—or in a CMO partnership—they mean less than a well-understood batch record. Each shipment includes a clear mapping of material to prior batch histories, analytical methods, and any changes from previous lots.
Our use of analytical transparency, from high-resolution NMR to LC-MS impurity footprints, developed in response to specific feedback from partners. One customer flagged an unexpected minor isomer showing up in a late-stage step; only by digging into the chromatographic data at parts-per-million sensitivity—documented in every certificate—could root causes be determined and eliminated. This ongoing dialog with research groups shapes the data we include.
Sourcing tert-butyl (3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate from a manufacturer reflects a strategic decision: entrusting the up-front control work to a partner with both technical depth and a willingness to adapt protocols in response to project realities. The high cost of a failed intermediate or out-of-specification analog is more than budget—it touches wasted time, missed grant milestones, and the domino effect on downstream syntheses.
Throughout the compound’s production, no single run resembles the last. The reagents, environmental conditions, and even small changes in water activity or salt form can drive subtle shifts in outcome. As a direct manufacturer, we don’t just rely on literature procedures: every batch is documented, and every deviation sparks a troubleshooting cycle. No lab notebook entry disappears into a drawer.
Customization happens frequently. A university group requested the same scaffold with a tightly constrained residual solvent profile, for use in an organocatalyst screen; another pharma team needed a specific particle size for direct reactor charging. Our technical staff engaged early to confirm targets and offer alternatives where needed. This flexibility stems from building methods in-house, where answers don’t wait for a third-party check.
Comparisons come up often. Colleagues or procurement staff want to know how this intermediate stacks against other statin-like or pyrrole-derived systems, either available from other suppliers or synthesized in-house.
From direct experience, differences become tangible at the level of structural integrity, purity, and supply reliability. Competing products can sometimes drift in enantiomeric composition or carry legacy process contaminants. Especially for this class, eliminating persistent metal catalysts, hydrazine residues, and fluorinated byproducts means more than an abstract exercise—it’s the difference between a stalled pilot campaign and a successful bioassay run.
Our knowledge base contains records from dozens of customer projects. We recall a development campaign where a closely related analog—sourced without thorough pre-screening—introduced subtle profile drift in downstream biological tests. The problem took weeks to isolate and, after switching to our consistently specified product, results snapped back on track. Experience like this illustrates why deep familiarity with the whole synthetic process—not just the final purity spec—matters for reproducible science.
Much chemical supply today moves through layers of distribution or outsourcing. Yet only by managing reactors ourselves, optimizing routes at bench scale and translating them to plant runs, do we keep control over every input, every trace impurity, every shipment lot.
No two plant campaigns are alike. Reactors, pumps, and even glassware swaps introduce variation. Our supervisors walk the shop floor, run sample splits to confirm batch trends, and rapidly course-correct if a raw material batch shows drift. Automation helps, but so too does old-school watchfulness—calling in a senior chemist to assess an unexpected HPLC peak or troubleshooting a filtration bottleneck before it blocks delivery.
We take pride in rapid response. If a scientist on a collaborative team finds data that doesn’t line up—a new impurity appears, a melting point surprises—we open up the process. Data flows back from the customer bench to our own R&D group with no bureaucratic slowdown. Fielding these challenges doesn’t just keep projects on track—it raises the bar for our product line, and every challenge builds our collective knowledge for future batches.
Long-term storage or delayed use brings its own set of hurdles for complex organics. Early on, we learned that hydration, packing geometry, and shipping temperature affect the shelf stability of tert-butyl (3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate. An overly dry storage container, or one left open in humid air, can push down stability windows.
We work with customers to match batch presentation to intended storage and handling—solid, semi-solid, protected atmosphere, or pre-split aliquots for multi-site research teams. Batch records track specific storage protocols and timelines; if any lot deviates from expectation, data logs guide the root cause search. Researchers benefit directly: fewer late surprises, more on-schedule experiments.
Our quality system tracks every stability profile. A mid-sized biotech flagged a solubility lag after several months at standard warehouse conditions—not a recall-level event, but enough to disrupt a set of key experiments. Our team used analytically-driven forensics to determine the culprit and reformulate packaging for subsequent lots, closing the loop between field discovery and plant process.
Expectations around analytical depth and reliability keep evolving. Early on, projects might prioritize timelines over multi-method material characterization. Over the years, many customers have circled back after running into trouble with less rigorously specified supply—unaccounted for isomeric drift, undetected polymeric residues, or instability in custom synthetic blocks.
The push for traceability—from batch signoff through long-term analytical archives—shaped our internal practices. Our chemists track not just what a batch looks like the day it ships, but how its profile trends over time, long after it leaves our site. This matters for anyone working on preclinical or clinical pipelines, where reproducibility sets the stage for regulatory readiness.
Working with direct manufacturing access, customers as well as our own chemists gain leverage to troubleshoot, iterate, and innovate. Any process tweak, any skipped wash or change in solvent grade, echoes through into finished stock. Our job is stewardship: making sure those echoes carry useful information, not silent risks.
Modern synthesis can’t ignore the footprint it leaves. Our experience with tert-butyl (3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate began with small, solvent- and energy-intensive routes. These early campaigns produced high purity at a higher resource cost.
As demand grew, we made process changes to reduce solvent burden, reclaim spent reagents, and minimize inorganic waste streams. On-site analytical recycling, greener solvent recovery systems, and batch yield improvements have cut waste without touching product quality. These are not just slogans; customers ask about them routinely in bidirectional site visits. The practical lesson: greener processes are also more reliable and cost-effective in the long run.
Safe handling, both in the plant and in customers’ own labs, gets built into every dialogue. Large-scale production experience gives us firsthand knowledge of risks in scale-up—heat release events, pressure surges, trace volatile formation—which we share directly with collaborators. Our open-door policy ensures no customer is left guessing about handling precautions, even for the most custom-dosed experiments.
Medicinal chemistry keeps accelerating, driven by demands for potent, selective molecules with well-understood provenance. tert-Butyl (3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate is more than a research supply item—it's the result of deliberate, iterative collaboration between synthetic chemists, process engineers, and customers with one common goal: building out frontiers in drug discovery.
Our experience has taught us that off-the-shelf solutions seldom fit the needs of advanced creative work. Direct engagement with both API innovators and academic pioneers shapes the evolution of our offerings, driving not just purity and analytical fidelity but pragmatic flexibility for each campaign. The future lies not in static catalog products, but in responsive partnerships grounded in mutual respect, analytical transparency, and a willingness to roll up sleeves together.
Each gram of tert-butyl (3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate represents a shared investment in the success of boundary-pushing science. The boundaries do not stop at production—they reach deep into analytical support, tailored delivery, and shared troubleshooting through every phase of project evolution.
This collaborative approach—direct, experienced, and continually refined—sets apart what direct manufacture can offer. The compound’s complexity is more than an analytical challenge; it is a bridge between demanding chemistry and the achievements of teams who depend on rock-solid starting points. As new research priorities emerge, as novel targets come into view, we stand committed to pushing our tools, our know-how, and our product capabilities forward, shoulder to shoulder with scientists charting the path.